Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-26
2008-08-26
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388220, C530S388700, C536S023100, C536S023530
Reexamination Certificate
active
07417128
ABSTRACT:
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-I and b7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5116964 (1992-05-01), Capon
patent: 5304635 (1994-04-01), Imam
patent: 5434131 (1995-07-01), Linsley
patent: 5521288 (1996-05-01), Linsley
patent: 5580756 (1996-12-01), Linsley
patent: 5747034 (1998-05-01), De Boer
patent: 5770197 (1998-06-01), Linsley
patent: 5844095 (1998-12-01), Linsley
patent: 5885579 (1999-03-01), Linsley
patent: 6051228 (2000-04-01), Aruffo
patent: 6113898 (2000-09-01), Anderson
patent: 6162432 (2000-12-01), Wallner
patent: 6709654 (2004-03-01), Anderson
patent: 6893638 (2005-05-01), Anderson
patent: 7153508 (2006-12-01), Anderson et al.
patent: 7192585 (2007-03-01), Anderson
patent: 7323170 (2008-01-01), Anderson et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 194 276 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: WO 87/01131 (1987-02-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/06193 (1992-04-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/09812 (1993-05-01), None
patent: WO 93/20210 (1993-10-01), None
patent: WO 94/01547 (1994-01-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 95/22619 (1995-08-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 96/40878 (1996-12-01), None
patent: WO 98/19706 (1998-05-01), None
Alegre M., et al, “Effect of single amino acid mutation on the activating and immunosuppressive properties of a “Humanized” OKT3 monoclonal antibody,” J. Immunol., 1992, 148:3461-3468.
Armitage R.J., et al., “Molecular and biological characterization of a murine ligand for CD40,” Nature, 1992, 357:80-82.
Azuma M., et al., “CD28 Interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small resting T lymphocytes,” J. Exp. Med., 1992, 175:353-360.
Azuma M., et al., “Functional expression of B7/BB1 on activated T lymphocytes,” J. Exp. Med., 1993, 177:845-850.
Azuma M.D., et al., “B7 antigen is a second ligand for CTLA-4 and CD28,” Nature, 1993, 366:76-79.
Barbas III, et al. “Human monoclonal Fab frgments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity,” Proc. Natl. Acad. Sci. U.S.A., 1992, 89: 10164-10168.
Ben-Nun A., et al., “The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis,” Eur J. Immunol., 1981, 11:195-199.
Blazar B.R., et al., “Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells,” J Immunol., 1996, 157:3250-3259.
Boussiotis V.A., et al., “Activated human B lymphocytes express three CTLA-4 counter-receptors that co-stimulate T-Cell activation,” Proc. Natl. Acad. Sci., USA, 1993, 90:11059-11063.
Capon D.J., et al., “Designing CD4 immunoadhesins for AIDS therapy,” Nature, 1989, 337, 525-531.
Chen et al. “Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes.” J. Immunol., 1994, 152 (5):2105-2114.
Cohen J., “Mounting a targeted strike on unwanted immune responses,” (news; comment), Science, 1992, 257:751.
Cohen J., “New protein steals the show as ‘costimulator’ of T cells,” Science, 1993, 262:844-845.
Daikh et al., “The CD28-B7 costimulatory pathway and its role in autoimmune disease,” J. Leukos. Biol., 1997, 62(2):156-162.
Dautigny A., et al., “Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid,” FEBS Lett., 1985, 188(1):33-36.
Davila-Bloom et al., “Monoclonal antibody studies of the antigenic determinants of human plasma retinol-binding protein.” J. Nutr. Biochem, 1990, 1(5):262-71 (abstract only).
De Boer M., et al., “Functional characterization of a novel Anti-B7 monoclonal antibody,” Eur. Journal of Immunology, 1992, 22:3071-3075.
Delabie J., et al., “The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines,” Blood, 1993, 82:2845-2852.
Dermer G.B., et al., “Another anniversary for the war on cancer,” Biotechnology, 1994, 12:320.
Dillman R.O., et al., “Antibodies as cytotoxic therapy,” J Clin Oncol., 1994, 12:1497-1515.
Durie F.H., et al., “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40,” Science, 1993, 261:1328-1330.
Durie F.H., et al., “The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease,” Research in Immunology, 1994, 145(3), 200-205 & 244-249.
Engel et al, “The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen,” Blood, 1994, 84:1402-1407.
Falini B., et al., “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin,” The Lancet, 1992, 339:1195-1196.
Freeman G.J., et al., “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation,” Science, 1993, 262:909-911.
Freeman G.J., et al., “CTLA-4 and CD28 MRNA are Coexpressed in most T cells after activation,” The Journal of Immunology, 1992, 149:3795-3801.
Freeman G.J., et al., “Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7,” J. Exp. Med., 1991, 174:625-631.
Freeman G.J., et al., “Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice,” Science, 1993, 262:907-909.
Geenen V. and G. Kroemer, “Multiple ways to cellular immune tolerance,” Immunology Today, 1993, 14:573.
Gerritse K., et al., “CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis,” Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
Gimmi C.D., et al., “Human T-cell clonal anergy is Induced by antigen presentation in the absence of B7 costimulation,” Proc. Natl. Acad. Sci., 1993, 90:6586-6590.
Gottlieb A., et al., “Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody,” J Am Acad Dermatol., 2002, 47:692-700.
Gottlieb A., et al., “Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis,” J Invest Dermatol., 2000, 114:840, Abstract No. 546.
Gottlieb A.B. et al. “Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal Antib
Anderson Darrell R.
Brams Peter
Hanna Nabil
Biogen Idec Inc.
Gambel Phillip
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
7C10 and 16C10 CD80-specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7C10 and 16C10 CD80-specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7C10 and 16C10 CD80-specific antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4000251